biostudies-literatureMatthay MANHLBI NIH HHS965-72https://www.ebi.ac.uk/biostudies/studies/S-EPMC2951759biostudies-literatureUnknown138(4)Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSC) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI). This article provides a brief review of the biologic qualities of MSC that make them suitable for the treatment of human diseases, as well as the experimental data that provide support for their potential efficacy for critically ill patients with acute respiratory failure from ALI. The article then discusses which patients with ALI might be the best candidates for cell-based therapy and provides a template for the regulatory and practical steps that will be required to test allogeneic human MSC in patients with severe ALI. There is a dual focus on how to design trials for testing both safety and efficacy.ChestTherapeutic potential of mesenchymal stem cells for severe acute lung injury.PMC2951759R37 HL51856R01 HL051854R01 HL51854HL090833N01HB37164K08 HL093026R37HL51856R37 HL051856K23 HL090833HL093026Calfee CSRead EJMcKenna DHThompson BTLiu KDMatthay MALee JWfalseTherapeutic potential of mesenchymal stem cells for severe acute lung injury.Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSC) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI). This article provides a brief review of the biologic qualities of MSC that make them suitable for the treatment of human diseases, as well as the experimental data that provide support for their potential efficacy for critically ill patients with acute respiratory failure from ALI. The article then discusses which patients with ALI might be the best candidates for cell-based therapy and provides a template for the regulatory and practical steps that will be required to test allogeneic human MSC in patients with severe ALI. There is a dual focus on how to design trials for testing both safety and efficacy.2010-01-01T00:00:00Z2010 Oct2024-11-21T08:53:03.111Z2019-03-27T00:34:43ZS-EPMC29517592092380010.1378/chest.10-0518